| Status: Under consideration by AWMSG Scrutiny Panel | |
For the off-label maintenance treatment of acute myeloid leukaemia (AML) in patients with FLT3 mutation and evidence of minimum residual disease, before or after haematopoietic stem cell transplant. |
|
Medicine details |
|
| Medicine name | gilteritinib (Gilteritinib Astellas®) |
| Formulation | 40 mg film-coated tablet |
| Reference number | 3663 |
| Indication | As above |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | Under consideration |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 05/02/2026 |